Bupropion is marketed as an antidepressant drug under the brand name Wellbutrin, and as an aid to smoking cessation under the brand name Zyban. An entry on bupropion is available in Wikipedia.
SNPs in the region of the DRD2 gene have been studied in terms of their impact on the efficacy of the use of bupropion. In particular, rs1800497 may strongly influence whether Zyban helps a person stop smoking.
The newest competitor to Zyban is Chantix, the trade name for varenicline. No SNPs are known at this time to influence the efficacy of Chantix.
journal antipsychotics (Abilify, Risperdal, Seroquel), antidepressants (Prozac, Wellbutrin, Effexor, Paxil, Zoloft), anticonvulsants (Lamictal, Depakote, Trileptal, Klonopin, Topamax), and the stimulant (Concerta) metabolism affected by variations in CYP2C9, CYP2C19, and CYP2D6
|Genotype/Genoset||Diplotype||Gene||Drug Use/Category/Class||Medical Field||Summary||Descriptive Sentence|
|rs1800497(C;C)||A2/A2||ANKK1||Smoking Cessation||Psychiatry||Normal Response Expected||You have the ANKK1 genotype with the highest likelihood of quitting smoking when prescribed bupropion.|
|rs1800497(C;T)||WT/A2||ANKK1||Smoking Cessation||Psychiatry||Consider Alternatives||You have an ANKK1 genotype with lower odds of quitting smoking when prescribed bupropion.|
|rs1800497(T;T)||WT/WT||ANKK1||Smoking Cessation||Psychiatry||Consider Alternatives||You have an ANKK1 genotype with lower odds of quitting smoking when prescribed bupropion.|